Jms Co.,Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020
February 05, 2020
Share
JMS Co.,Ltd. announced consolidated earnings results for the nine months ended December 31, 2019. For the period, the consolidated company reported net sales of ¥43,552 million, operating profit of ¥1,497 million, ordinary profit of ¥1,720 million, profit attributable to owners of the parent of the company of ¥1,176 million or net income per share of ¥48.26 compared to net sales of ¥44,251 million, operating profit of ¥1,374 million, ordinary profit of ¥1,419 million, profit attributable to owners of the parent of the company of ¥980 million or net income per share of ¥40.22 for the same period last year.
For the full year of fiscal year ending March 31, 2020, the consolidated company expects net sales of ¥60,000 million, operating income of ¥1,800 million, ordinary income of ¥2,000 million, profit attributable to owners of the parent of the company of ¥1,400 million or basic earnings per share of ¥57.43.
JMS CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and drugs. The Company operates through five geographical segments including Japan, Singapore, China, Philippines and Germany. The Company is engaged in the manufacture and sale of infusion and nutrition products, dialysis products, surgery products, blood and cell products and other products. The Companyâs main products include infusion & transfusion set, syringe pump, surgical gown, dialysis kit, peritoneal dialysate, microcatheter, blood bag, among others. The Company is also involved in the provision of maintenance service and other related services.
Jms Co.,Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020